Treace Medical Concepts (TMCI)
(Delayed Data from NSDQ)
$5.88 USD
+0.13 (2.26%)
Updated May 31, 2024 04:00 PM ET
After-Market: $5.90 +0.02 (0.34%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Treace Medical Concepts (TMCI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.14 | $17.00 | $5.50 | 58.96% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Treace Medical Concepts comes to $9.14. The forecasts range from a low of $5.50 to a high of $17.00. The average price target represents an increase of 58.96% from the last closing price of $5.75.
Analyst Price Targets (7 )
Broker Rating
Treace Medical Concepts currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 7 | 7 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 1.29 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/8/2024 | BTIG | Ryan Zimmerman | Strong Buy | Hold |
5/8/2024 | Truist Securities | Richard Newitter | Strong Buy | Hold |
1/16/2024 | Stephens | George Sellers | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 7 |
Average Target Price | $9.14 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | -0.29 |